Efficacy, Safety, and Pharmacokinetic Profile of Etokimab (ANB020) in Adult Participants With Moderate-to-Severe Atopic Dermatitis (ATLAS)
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study Investigating the Efficacy, Safety, and Pharmacokinetic Profile of ANB020 Administered to Adult Subjects With Moderate-to-Severe Atopic Dermatitis
Sponsor: AnaptysBio, Inc.
This PHASE2 trial investigates Atopic Dermatitis and is currently completed. AnaptysBio, Inc. leads this study, which shows 13 recorded versions since 2018 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
13 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jun 2023 — Jul 2024 [monthly]
Completed PHASE2
Status: Unknown Status → Completed
-
Oct 2021 — Jun 2023 [monthly]
Unknown Status PHASE2
Status: Recruiting → Unknown Status
▶ Show 8 earlier versions
-
Jan 2021 — Oct 2021 [monthly]
Recruiting PHASE2
-
Jun 2019 — Jan 2021 [monthly]
Recruiting PHASE2
-
Apr 2019 — Jun 2019 [monthly]
Recruiting PHASE2
-
Dec 2018 — Apr 2019 [monthly]
Recruiting PHASE2
-
Oct 2018 — Dec 2018 [monthly]
Recruiting PHASE2
-
Aug 2018 — Oct 2018 [monthly]
Recruiting PHASE2
-
Jul 2018 — Aug 2018 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Jun 2018 — Jul 2018 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- AnaptysBio, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Albany, United States , Albuquerque, United States , Bad Bentheim, Germany , Bay City, United States , Berlin, Germany , Bialystok, Poland , Birmingham, United States , Bonn, Germany , Boston, United States , Brno, Czechia and 65 more locations